MET alterations in advanced non-small cell lung cancer

Targeting the MET pathway in advanced NSCLC has been of particular interest due to its role as both a primary oncogenic driver and secondary oncogenic driver of acquired resistance. Activation of the MET pathway can occur through several mechanisms, which can complicate the diagnostic and treatment approach. Recently, several MET-directed therapies have been developed with promising results. In this narrative review, we sum-marize the biology and mechanism of MET as a clinically relevant driver mutation, distinct MET alterations including diagnostic challenges, significance in the setting of acquired resistance, and novel treatment strategies in advanced NSCLC.

Automated summary

Targeting the MET pathway is an important approach in the treatment of advanced NSCLC, as it plays a role in both primary oncogenesis and acquired resistance. However, the various mechanisms of MET pathway activation can complicate diagnosis and treatment. Recent developments in MET-directed therapies show promising results. This review summarizes the biology, mechanisms, diagnostic challenges, importance in acquired resistance, and novel treatment strategies of MET in advanced NSCLC.